Urolog. pro Praxi, 2009; 10(5): 282-286

Bisphosphonates in treating bone lesions in urology

MUDr. Michaela Matoušková, doc. MUDr. Miroslav Hanuš CSc
Urocentrum Praha, s.r.o

High incidence of bone metastatic disease has been typical for many malignant cancers, incl. urological tumors. Thanks to the effect of

oncological therapy growing number of patients survive. Bone metastases and its complications remarcably shorten length of the bearers

life and lowered their quality of life. Bisphosphonates therapy in cases with bone metastases are, at present, part of complex therapy.

Modern therapeutic modalities using the bisphosphonates cytotoxic effect present shisf from only palliative therapy to the curative

adjuvant regimens.

Keywords: bone metastatic disease, SRE, bisphosphonates.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matoušková M, Hanuš M. Bisphosphonates in treating bone lesions in urology. Urol. praxi. 2009;10(5):282-286.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14(20): 6690-6696. Go to original source... Go to PubMed...
    2. Matoušková M, Hanuš M, Dudková V, Tejčková E, Řehák J. Může laboratorní diagnostika pomocí 1CTP omezit počet scintigrafií skeletu? In: Valík D. Edukační sborník BOD 2009, XXXIII. BOD, Dataprint Brno, 2009: 70 s.
    3. Katolická J. Využití bisfosfonátů v léčbě karcinomu prostaty. Farmakoterapie 2008; 5: 517-521.
    4. Adam Z, Ševčík P, Vorlíček J, a kol. Kostní nádorová choroba. Praha: Grada Publishing, 2005: 296 s.
    5. Body JJ, Lichinitser M, Toulandin, S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastase Annals of Oncology Advance Access 2007; 1-7. Go to original source... Go to PubMed...
    6. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008; 19(3): 420-432. Go to original source... Go to PubMed...
    7. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 7: 1972-1982. Go to original source... Go to PubMed...
    8. Coleman RE Bisphosphonates in breast cancer Ann Oncol 2005; 16: 687-695.
    9. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744. Go to original source... Go to PubMed...
    10. Robertson AG, Rees NS, Ralston SH. Effect of oral clodronate on metastatic bone pan: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427-2430. Go to original source... Go to PubMed...
    11. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasi due to hormone refraktory prostate cancer. J Urol 2001; 165: 136-140. Go to original source... Go to PubMed...
    12. Kolombo I, Kolombová, J, Vlásek T. Místo bisfosfonátů při skeletovém postiženív uroonkologii. Urol pro praxi 2006; 5: 228-242.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.